Medical supply chain risk became a board-level topic in 2020 and has not gone back to where it was. The healthcare buyers that came through 2020–2023 best were the ones who had already invested in supply chain resilience — and the ones who hadn't, learnt the hard way. These are the seven levers we see making the biggest difference.
Lever 1: supplier diversification. Single-source dependencies on critical SKUs are the biggest concentration risk in healthcare supply chains. Dual-source where regulatory permits and where unit economics support it.
Lever 2: regulatory pre-clearance. Regulatory documentation arriving wrong, late, or in the wrong format is the biggest source of avoidable delay. Pre-clearance against the destination-market requirement before cargo leaves origin removes the risk.
Lever 3: cold-chain validation. Validated cold-chain packaging and continuous temperature monitoring prevent the unobserved excursions that compromise reagents and biologics.
Lever 4: inventory strategy. For critical-care consumables, build deliberate inventory buffers rather than running just-in-time. The working capital cost is real but smaller than the cost of a stock-out.
Lever 5: supplier monitoring. Continuous monitoring of supplier signals (regulator action lists, recalls, sanctions, corporate distress) catches risk before it becomes a delivery problem.
Lever 6: documented recall procedure. Recalls happen. The difference between a manageable recall and a regulatory event is the recall procedure being documented, drilled, and supported by lot / serial traceability.
Lever 7: dual-region sourcing. For multi-region buyers, source the same SKU from manufacturers in two regions where possible — gives optionality if a region becomes constrained.